Akari Therapeutics Plc (AKTX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Akari Therapeutics (AKTX) focuses on developing biopharmaceuticals to combat severe autoimmune disorders by utilizing complement regulation mechanisms. This price chart on GURU.Markets reflects an EV/EBITDA ratio of 0.00. The company is currently funded by investments as it develops treatments for orphan immune pathologies; however, post-merger integration and high costs associated with late-stage trials create significant financial risks.
Akari Therapeutics Plc - analytical breakdowns and key metrics (AKTX)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
- business earnings and investment ratios data:
AKTX - Net Profit|Expected Profit Akari Therapeutics|AKTX - Company Value to Net Income|Forward P/E Multiple Akari Therapeutics PLC|AKTX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Akari Therapeutics PLC|AKTX - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Akari Therapeutics|AKTX - Earnings per share for the last four quarters|Quarterly EPS earnings growth akaritx.com|AKTX - Earnings per share increase in current year|Earnings growth forecast for next year Akari Therapeutics
- sales and revenue data:
Initial company analysis:Akari Therapeutics, Plc AKTX
This ratio correlates the total enterprise value with its operating profit before depreciation and amortization, allowing for the determination of the asset's fundamental undervaluation regardless of the debt load. An analysis of the EV/EBITDA metric for a capital-intensive business helps assess the efficiency of Akari Therapeutics (AKTX), taking into account the costs of environmental modernization of laboratories and the implementation of biodegradable packaging as part of its ESG strategy.
Competitors of Akari Therapeutics
EV/EBITDA Multiple ARGX (argenx.com)|Total Company Value to Operating Income Before Depreciation Ratio biontech.de (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADMA Biologics Inc (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist Corp (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant, Inc.|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple grifols.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies Corp (ADPT)|Celldex Therapeutics, Inc. - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (auriniapharma.com)|BioCryst Pharmaceuticals Inc (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|DNTH (Dianthus Therapeutics) - Enterprise Value to Operating Income Before Depreciation|PHVS: EV/EBITDA Multiple|ABCL (AbCellera Biologics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio TRML|Company Value to EBITDA Intrexon PGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming Group N.V. (PHAR)|Enterprise Value to Operating Income Before Depreciation Ratio NKTR|EV/EBITDA Multiple UPB (Upstream Pharma)|Total Company Value to Operating Income Before Depreciation Ratio Zenas Biopharma, Inc. (ZBIO)|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Gossamer Corp (GOSS) - Enterprise Value to EBITDA Ratio|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation SEPN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals|Savara Inc (SVRA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RIGL|Total Company Value to Operating Income Before Depreciation Ratio AnaptysBio Inc.|EV/EBITDA Multiple ATXS (Astria Therapeutics Inc)|enGene Holdings Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation JBIO (aerovatetx.com)|Aclaris (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kyverna - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TLSA|Company Value to EBITDA Cabaletta Bio CABA|EV/EBITDA Multiple VTYX|Theratechnologies (THTX) - Enterprise Value to EBITDA Multiple|Avalo Therapeutics - Enterprise Value to EBITDA Ratio|Eledon Pharmaceuticals (ELDN) - Company Value to EBITDA|Agenus, Inc - EV/EBITDA Multiple|Company Value to EBITDA climbbio.com|ZURA (Zura Bio Limited) - Enterprise Value to EBITDA Ratio|aTyr (ATYR) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ADAG|IMA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Therapeutics (STTK)|Enterprise Value to EBITDA Ratio Equillium EQ|Connect Biopharma Holdings Limited - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation IMUX|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|inflarx.de (IFRX) - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation X4 Pharmaceuticals XFOR|ACET - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization celularity.com|INMB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BRNS|EV/EBITDA Multiple Kezar Life Sciences Inc (KZR)|EV/EBITDA Multiple SABS (SAB Biotherapeutics)|ENLV (Enlivex Therapeutics, Ltd.) - Company Value to Operating Income Before Depreciation Ratio|QTTB: Enterprise Value to EBITDA Ratio|GOVX - EV/EBITDA Multiple|Edesa Biotech Corp (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IBIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization carismatx.com|XTLB: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics Inc. (BOLT)|HCWB (HCW Biologics) - Business Value to Operating Income Before Depreciation|Aptevo Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple AIM ImmunoTech Inc. AIM|Aditxt Inc. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation GRI (GRI Bio, Inc.)|XORTX Therapeutics Inc (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio ReShape Lifesciences|Enterprise Value to EBITDA Ratio REVB|Indaptus Corp (INDP) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scinai.com (SCNI)|Enterprise Value to EBITDA Ratio CalciMedica CALI|EV/EBITDA Multiple AFMD (affimed.com)|Allakos Inc. (ALLK) - Company Value to EBITDA|HOOKIPA - EV/EBITDA Multiple|IGMS (igmbio.com) - Enterprise Value to Operating Income Before Depreciation|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation OCEA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC BioPharm|Third Harmonic Bio Inc. (THRD) - Total Company Value to Operating Income Before Depreciation Ratio
